Pfizer’s Sales of Covid Vaccine Could Break Records Again
For two years in a row, the company is on track to bring in more single-year revenue from the shots than any other medical product in history.
Pfizer’s Covid vaccine could break sales records again next year.
A container with doses of Pfizer-BioNtech coronavirus vaccines was unloaded at Benito Juarez International Airport in Mexico City earlier this year.Credit…Hector Vivas/Getty Images
Nov. 2, 2021, 1:41 p.m. ET
With its coronavirus vaccine on track this year to generate the biggest single-year sales ever for a medical product, Pfizer on Tuesday disclosed revenue projections indicating that the shot will likely beat that record or come close in 2022.
The company said while reporting its third quarter earnings that it expects its vaccine to bring in $36 billion in revenue this year. Pfizer said it has already reached supply deals worth $29 billion in revenue for its vaccine next year, covering 1.7 billion shots it has already committed to countries around the world. Billions more in sales are likely to come as the company reaches more deals to sell to governments the four billion shots it expects to produce next year.
The company’s chief executive, Dr. Albert Bourla, told analysts on Tuesday that most of the company’s negotiations are with high- and upper-middle-income countries. He said he was concerned that poorer countries and their proxies were not lining up to place orders. “I don’t want to reach a level that again the low- and middle-income countries will be behind in their deliveries because they didn’t place their orders,” he said.
Pfizer says it is selling shots for poorer countries at discounted prices, but many of the world’s poorest countries cannot afford to buy doses directly. They have depended on donations from the United States and other wealthy countries, and on supply from Covax, the United Nations program to vaccinate the globe.
There remain stark differences in vaccine access: Worldwide, about 75 percent of all shots that have gone into arms have been administered in high- and upper-middle-income countries, according to the Our World in Data project at the University of Oxford. Only 0.6 percent of doses have been administered in low-income countries.
The enormous sales figures will translate into billions in profits for Pfizer. The company, which must split its vaccine revenue with development partner BioNTech, said that it expects its profit margins on the vaccine will be in the high 20 percent range next year, the same margin it projected this year.
The doses that will be delivered next year include booster shots, mostly for wealthier countries, and primary immunizations, with an emphasis on second doses, for poorer countries.
A small chunk of the doses will be given to children. The company won authorization last week for its vaccine to be given in the United States to children between the ages of 5 and 11. An advisory panel to the Centers for Disease Control and Prevention is meeting Tuesday regarding pediatric doses for that age group and it is expected to make recommendations to the agency about how the vaccine should be used. If the director signs off, children could begin receiving it this week.
Pfizer expects to have initial data from its studies evaluating its vaccine in children between the ages of 2 and 4 by the end of December and in children between the ages of six months and 1 by the end of March, the company’s research chief, Dr. Mikael Dolsten, told analysts on Tuesday.
Pfizer could get another revenue boost next year from an antiviral pill it is developing for high-risk Covid patients early in their infections. Results are expected within the next few months from a key clinical trial evaluating whether the drug can cut the risk of hospitalizations and death.
A Pfizer executive, Angela Hwang, said the company sees a market of up to 150 million people for the pill. She called it a “durable opportunity,” saying that governments may be interested in stockpiling the drug.
A rival pill from Merck, known as molnupiravir, has already been shown to halve the risk of hospitalization in similar patients. Merck said last week that it expects molnupiravir to generate between $5 and $7 billion in revenue globally through the end of next year.